Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Personalised melanoma vaccine cuts risk of recurrence

Adding a personalised, mRNA-based cancer vaccine to standard immunotherapy after surgery for...

Research project to produce fish-free omega-3

SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...

Biodegradable smart patch can detect and treat blood clots

Researchers have developed a biodegradable smart patch that detects pressure changes and releases...

Content from other channels on our network

Novel method to reduce metal waste in manufacturing

ARENA backs hydrogen technology for steelmaking pilot

CSIRO suggests ways Australia can grow battery manufacturing sector

MathWorks certified to provide guidance for AI‍-‍assisted engineering

NSW opens expressions of interest for Bradfield enterprise precinct

Smart bedding targets falls risk in aged care

Calvary confirms some services across two hospitals "will not be offered"

Opinion: Beyond connectivity — making health data meaningful across systems

Winning healthcare equipment tenders: why having the best product is no longer enough

Optimising connectivity: Peninsula University Hospital

pladis program plans to help with a snacking reshape

Food safety testing hub opens in Melbourne

Contamination detection solutions for the food manufacturing industry

Six on the shelf: diverse new food products in November

tna's food packaging solution wins gold at the Good Design Awards 2026